nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SLC22A4—larynx—thyroid cancer	0.0564	0.141	CbGeAlD
Procainamide—Pericarditis—Vandetanib—thyroid cancer	0.0367	0.071	CcSEcCtD
Procainamide—DNMT1—saliva-secreting gland—thyroid cancer	0.0188	0.0471	CbGeAlD
Procainamide—Sunitinib—RET—thyroid cancer	0.0181	1	CrCbGaD
Procainamide—SCN11A—head—thyroid cancer	0.0156	0.0391	CbGeAlD
Procainamide—SCN7A—thyroid gland—thyroid cancer	0.015	0.0374	CbGeAlD
Procainamide—SLC22A4—neck—thyroid cancer	0.015	0.0374	CbGeAlD
Procainamide—DNMT1—trachea—thyroid cancer	0.0145	0.0363	CbGeAlD
Procainamide—Pleural effusion—Sorafenib—thyroid cancer	0.014	0.0271	CcSEcCtD
Procainamide—SCN7A—head—thyroid cancer	0.0133	0.0332	CbGeAlD
Procainamide—Atrial fibrillation—Vandetanib—thyroid cancer	0.0122	0.0235	CcSEcCtD
Procainamide—SCN8A—head—thyroid cancer	0.0118	0.0296	CbGeAlD
Procainamide—Cardiac failure—Vandetanib—thyroid cancer	0.0118	0.0228	CcSEcCtD
Procainamide—Lethargy—Vandetanib—thyroid cancer	0.0118	0.0228	CcSEcCtD
Procainamide—DNMT1—thyroid gland—thyroid cancer	0.0115	0.0288	CbGeAlD
Procainamide—Cardiac arrest—Vandetanib—thyroid cancer	0.011	0.0212	CcSEcCtD
Procainamide—SLC22A3—saliva-secreting gland—thyroid cancer	0.0106	0.0266	CbGeAlD
Procainamide—SCN4A—thyroid gland—thyroid cancer	0.0105	0.0262	CbGeAlD
Procainamide—DNMT1—head—thyroid cancer	0.0102	0.0255	CbGeAlD
Procainamide—ACHE—thyroid gland—thyroid cancer	0.00934	0.0234	CbGeAlD
Procainamide—Neutropenia—Vandetanib—thyroid cancer	0.00931	0.018	CcSEcCtD
Procainamide—SCN7A—lymph node—thyroid cancer	0.0093	0.0233	CbGeAlD
Procainamide—SCN4A—head—thyroid cancer	0.00928	0.0232	CbGeAlD
Procainamide—Pericarditis—Epirubicin—thyroid cancer	0.00915	0.0177	CcSEcCtD
Procainamide—SLC22A4—trachea—thyroid cancer	0.009	0.0225	CbGeAlD
Procainamide—SCN1A—head—thyroid cancer	0.00894	0.0224	CbGeAlD
Procainamide—Depression—Vandetanib—thyroid cancer	0.00885	0.0171	CcSEcCtD
Procainamide—Renal failure—Vandetanib—thyroid cancer	0.00873	0.0169	CcSEcCtD
Procainamide—Hepatic failure—Sorafenib—thyroid cancer	0.00865	0.0167	CcSEcCtD
Procainamide—Pericarditis—Doxorubicin—thyroid cancer	0.00847	0.0164	CcSEcCtD
Procainamide—SCN2A—head—thyroid cancer	0.00821	0.0205	CbGeAlD
Procainamide—SCN3A—thyroid gland—thyroid cancer	0.00813	0.0203	CbGeAlD
Procainamide—Bradycardia—Vandetanib—thyroid cancer	0.00812	0.0157	CcSEcCtD
Procainamide—Cardiac failure—Sorafenib—thyroid cancer	0.00797	0.0154	CcSEcCtD
Procainamide—SCN10A—head—thyroid cancer	0.00792	0.0198	CbGeAlD
Procainamide—SLC22A5—saliva-secreting gland—thyroid cancer	0.00772	0.0193	CbGeAlD
Procainamide—Cardiac disorder—Vandetanib—thyroid cancer	0.0074	0.0143	CcSEcCtD
Procainamide—SCN9A—lymph node—thyroid cancer	0.00728	0.0182	CbGeAlD
Procainamide—SCN3A—head—thyroid cancer	0.00721	0.018	CbGeAlD
Procainamide—SCN5A—head—thyroid cancer	0.00719	0.018	CbGeAlD
Procainamide—DNMT1—lymph node—thyroid cancer	0.00714	0.0179	CbGeAlD
Procainamide—SLC22A4—thyroid gland—thyroid cancer	0.00712	0.0178	CbGeAlD
Procainamide—Abdominal pain upper—Sorafenib—thyroid cancer	0.0071	0.0137	CcSEcCtD
Procainamide—Dysgeusia—Vandetanib—thyroid cancer	0.0068	0.0131	CcSEcCtD
Procainamide—SLC22A3—thyroid gland—thyroid cancer	0.00648	0.0162	CbGeAlD
Procainamide—Abdominal discomfort—Sorafenib—thyroid cancer	0.00644	0.0125	CcSEcCtD
Procainamide—Neutropenia—Sorafenib—thyroid cancer	0.00628	0.0122	CcSEcCtD
Procainamide—CHRM2—head—thyroid cancer	0.00612	0.0153	CbGeAlD
Procainamide—SLC22A1—head—thyroid cancer	0.00602	0.015	CbGeAlD
Procainamide—Convulsion—Vandetanib—thyroid cancer	0.00601	0.0116	CcSEcCtD
Procainamide—SLC22A5—trachea—thyroid cancer	0.00596	0.0149	CbGeAlD
Procainamide—Arthralgia—Vandetanib—thyroid cancer	0.00591	0.0114	CcSEcCtD
Procainamide—Renal failure—Sorafenib—thyroid cancer	0.00589	0.0114	CcSEcCtD
Procainamide—BCHE—trachea—thyroid cancer	0.0058	0.0145	CbGeAlD
Procainamide—ACHE—lymph node—thyroid cancer	0.0058	0.0145	CbGeAlD
Procainamide—SLC22A3—head—thyroid cancer	0.00575	0.0144	CbGeAlD
Procainamide—Hepatomegaly—Epirubicin—thyroid cancer	0.00559	0.0108	CcSEcCtD
Procainamide—Thrombocytopenia—Vandetanib—thyroid cancer	0.00555	0.0107	CcSEcCtD
Procainamide—SCN10A—lymph node—thyroid cancer	0.00554	0.0139	CbGeAlD
Procainamide—Hepatomegaly—Doxorubicin—thyroid cancer	0.00517	0.01	CcSEcCtD
Procainamide—Pleural effusion—Epirubicin—thyroid cancer	0.00517	0.01	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00516	0.00998	CcSEcCtD
Procainamide—SCN3A—lymph node—thyroid cancer	0.00505	0.0126	CbGeAlD
Procainamide—Cardiac disorder—Sorafenib—thyroid cancer	0.00499	0.00966	CcSEcCtD
Procainamide—Flushing—Sorafenib—thyroid cancer	0.00499	0.00966	CcSEcCtD
Procainamide—Decreased appetite—Vandetanib—thyroid cancer	0.00492	0.00953	CcSEcCtD
Procainamide—Pleural effusion—Doxorubicin—thyroid cancer	0.00478	0.00925	CcSEcCtD
Procainamide—SLC22A5—thyroid gland—thyroid cancer	0.00471	0.0118	CbGeAlD
Procainamide—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00463	0.00896	CcSEcCtD
Procainamide—BCHE—thyroid gland—thyroid cancer	0.00459	0.0115	CbGeAlD
Procainamide—Dysgeusia—Sorafenib—thyroid cancer	0.00458	0.00887	CcSEcCtD
Procainamide—Body temperature increased—Vandetanib—thyroid cancer	0.00448	0.00866	CcSEcCtD
Procainamide—Abdominal pain—Vandetanib—thyroid cancer	0.00448	0.00866	CcSEcCtD
Procainamide—SLC22A4—lymph node—thyroid cancer	0.00442	0.0111	CbGeAlD
Procainamide—Oliguria—Epirubicin—thyroid cancer	0.00429	0.00831	CcSEcCtD
Procainamide—Angioedema—Sorafenib—thyroid cancer	0.00428	0.00828	CcSEcCtD
Procainamide—BCHE—head—thyroid cancer	0.00407	0.0102	CbGeAlD
Procainamide—Asthenia—Vandetanib—thyroid cancer	0.00406	0.00786	CcSEcCtD
Procainamide—SLC22A3—lymph node—thyroid cancer	0.00403	0.0101	CbGeAlD
Procainamide—Pruritus—Vandetanib—thyroid cancer	0.00401	0.00775	CcSEcCtD
Procainamide—Myalgia—Sorafenib—thyroid cancer	0.00399	0.00771	CcSEcCtD
Procainamide—Arthralgia—Sorafenib—thyroid cancer	0.00399	0.00771	CcSEcCtD
Procainamide—Oliguria—Doxorubicin—thyroid cancer	0.00397	0.00769	CcSEcCtD
Procainamide—Ventricular tachycardia—Epirubicin—thyroid cancer	0.00396	0.00766	CcSEcCtD
Procainamide—Diarrhoea—Vandetanib—thyroid cancer	0.00388	0.0075	CcSEcCtD
Procainamide—Shock—Sorafenib—thyroid cancer	0.00376	0.00727	CcSEcCtD
Procainamide—Dizziness—Vandetanib—thyroid cancer	0.00375	0.00725	CcSEcCtD
Procainamide—Thrombocytopenia—Sorafenib—thyroid cancer	0.00374	0.00724	CcSEcCtD
Procainamide—Ventricular tachycardia—Doxorubicin—thyroid cancer	0.00366	0.00708	CcSEcCtD
Procainamide—Anorexia—Sorafenib—thyroid cancer	0.00364	0.00705	CcSEcCtD
Procainamide—Vomiting—Vandetanib—thyroid cancer	0.0036	0.00697	CcSEcCtD
Procainamide—Rash maculo-papular—Epirubicin—thyroid cancer	0.0036	0.00696	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00348	0.00673	CcSEcCtD
Procainamide—Nausea—Vandetanib—thyroid cancer	0.00336	0.00651	CcSEcCtD
Procainamide—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00333	0.00644	CcSEcCtD
Procainamide—Decreased appetite—Sorafenib—thyroid cancer	0.00332	0.00643	CcSEcCtD
Procainamide—Hepatic failure—Epirubicin—thyroid cancer	0.0032	0.00618	CcSEcCtD
Procainamide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00312	0.00604	CcSEcCtD
Procainamide—Urticaria—Sorafenib—thyroid cancer	0.00304	0.00587	CcSEcCtD
Procainamide—Body temperature increased—Sorafenib—thyroid cancer	0.00302	0.00584	CcSEcCtD
Procainamide—Abdominal pain—Sorafenib—thyroid cancer	0.00302	0.00584	CcSEcCtD
Procainamide—Renal impairment—Epirubicin—thyroid cancer	0.00302	0.00584	CcSEcCtD
Procainamide—Hepatic failure—Doxorubicin—thyroid cancer	0.00296	0.00572	CcSEcCtD
Procainamide—Cardiac failure—Epirubicin—thyroid cancer	0.00294	0.0057	CcSEcCtD
Procainamide—Lethargy—Epirubicin—thyroid cancer	0.00293	0.00567	CcSEcCtD
Procainamide—SLC22A5—lymph node—thyroid cancer	0.00293	0.00732	CbGeAlD
Procainamide—BCHE—lymph node—thyroid cancer	0.00285	0.00713	CbGeAlD
Procainamide—Hypersensitivity—Sorafenib—thyroid cancer	0.00281	0.00545	CcSEcCtD
Procainamide—Renal impairment—Doxorubicin—thyroid cancer	0.00279	0.0054	CcSEcCtD
Procainamide—Asthenia—Sorafenib—thyroid cancer	0.00274	0.0053	CcSEcCtD
Procainamide—Cardiac arrest—Epirubicin—thyroid cancer	0.00273	0.00528	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—thyroid cancer	0.00272	0.00527	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—thyroid cancer	0.00271	0.00525	CcSEcCtD
Procainamide—Pruritus—Sorafenib—thyroid cancer	0.0027	0.00523	CcSEcCtD
Procainamide—CYP2D6—head—thyroid cancer	0.0027	0.00675	CbGeAlD
Procainamide—Abdominal pain upper—Epirubicin—thyroid cancer	0.00262	0.00508	CcSEcCtD
Procainamide—Diarrhoea—Sorafenib—thyroid cancer	0.00261	0.00506	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—thyroid cancer	0.00253	0.00489	CcSEcCtD
Procainamide—Dizziness—Sorafenib—thyroid cancer	0.00253	0.00489	CcSEcCtD
Procainamide—Eosinophilia—Epirubicin—thyroid cancer	0.00246	0.00476	CcSEcCtD
Procainamide—Vomiting—Sorafenib—thyroid cancer	0.00243	0.0047	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—thyroid cancer	0.00243	0.0047	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—thyroid cancer	0.00232	0.00449	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—thyroid cancer	0.00227	0.0044	CcSEcCtD
Procainamide—Nausea—Sorafenib—thyroid cancer	0.00227	0.00439	CcSEcCtD
Procainamide—Renal failure—Epirubicin—thyroid cancer	0.00218	0.00421	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—thyroid cancer	0.00215	0.00416	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—thyroid cancer	0.00207	0.004	CcSEcCtD
Procainamide—Bradycardia—Epirubicin—thyroid cancer	0.00202	0.00391	CcSEcCtD
Procainamide—Renal failure—Doxorubicin—thyroid cancer	0.00201	0.0039	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—thyroid cancer	0.00191	0.0037	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—thyroid cancer	0.00187	0.00362	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—thyroid cancer	0.00184	0.00357	CcSEcCtD
Procainamide—Flushing—Epirubicin—thyroid cancer	0.00184	0.00357	CcSEcCtD
Procainamide—Chills—Epirubicin—thyroid cancer	0.00178	0.00345	CcSEcCtD
Procainamide—Flushing—Doxorubicin—thyroid cancer	0.00171	0.0033	CcSEcCtD
Procainamide—Cardiac disorder—Doxorubicin—thyroid cancer	0.00171	0.0033	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—thyroid cancer	0.00169	0.00328	CcSEcCtD
Procainamide—Chills—Doxorubicin—thyroid cancer	0.00165	0.00319	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—thyroid cancer	0.00161	0.00311	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—thyroid cancer	0.00157	0.00303	CcSEcCtD
Procainamide—Malaise—Epirubicin—thyroid cancer	0.00156	0.00302	CcSEcCtD
Procainamide—Convulsion—Epirubicin—thyroid cancer	0.0015	0.0029	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00149	0.00287	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—thyroid cancer	0.00147	0.00285	CcSEcCtD
Procainamide—Myalgia—Epirubicin—thyroid cancer	0.00147	0.00285	CcSEcCtD
Procainamide—Discomfort—Epirubicin—thyroid cancer	0.00146	0.00282	CcSEcCtD
Procainamide—Malaise—Doxorubicin—thyroid cancer	0.00144	0.00279	CcSEcCtD
Procainamide—Confusional state—Epirubicin—thyroid cancer	0.00142	0.00275	CcSEcCtD
Procainamide—Shock—Epirubicin—thyroid cancer	0.00139	0.00269	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—thyroid cancer	0.00139	0.00268	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—thyroid cancer	0.00138	0.00267	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—thyroid cancer	0.00136	0.00264	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—thyroid cancer	0.00136	0.00264	CcSEcCtD
Procainamide—Discomfort—Doxorubicin—thyroid cancer	0.00135	0.00261	CcSEcCtD
Procainamide—Anorexia—Epirubicin—thyroid cancer	0.00135	0.0026	CcSEcCtD
Procainamide—Hypotension—Epirubicin—thyroid cancer	0.00132	0.00255	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—thyroid cancer	0.00132	0.00255	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00129	0.00249	CcSEcCtD
Procainamide—Shock—Doxorubicin—thyroid cancer	0.00129	0.00249	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00128	0.00247	CcSEcCtD
Procainamide—Anorexia—Doxorubicin—thyroid cancer	0.00125	0.00241	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—thyroid cancer	0.00123	0.00237	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—thyroid cancer	0.00122	0.00236	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00119	0.0023	CcSEcCtD
Procainamide—Feeling abnormal—Epirubicin—thyroid cancer	0.00116	0.00225	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00115	0.00223	CcSEcCtD
Procainamide—Decreased appetite—Doxorubicin—thyroid cancer	0.00114	0.0022	CcSEcCtD
Procainamide—Urticaria—Epirubicin—thyroid cancer	0.00112	0.00217	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—thyroid cancer	0.00112	0.00216	CcSEcCtD
Procainamide—Abdominal pain—Epirubicin—thyroid cancer	0.00112	0.00216	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—thyroid cancer	0.00108	0.00208	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00107	0.00207	CcSEcCtD
Procainamide—Hypersensitivity—Epirubicin—thyroid cancer	0.00104	0.00201	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—thyroid cancer	0.00104	0.00201	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—thyroid cancer	0.00103	0.002	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—thyroid cancer	0.00103	0.002	CcSEcCtD
Procainamide—Asthenia—Epirubicin—thyroid cancer	0.00101	0.00196	CcSEcCtD
Procainamide—Pruritus—Epirubicin—thyroid cancer	0.000999	0.00193	CcSEcCtD
Procainamide—Diarrhoea—Epirubicin—thyroid cancer	0.000966	0.00187	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—thyroid cancer	0.000963	0.00186	CcSEcCtD
Procainamide—Asthenia—Doxorubicin—thyroid cancer	0.000937	0.00181	CcSEcCtD
Procainamide—Dizziness—Epirubicin—thyroid cancer	0.000934	0.00181	CcSEcCtD
Procainamide—Pruritus—Doxorubicin—thyroid cancer	0.000924	0.00179	CcSEcCtD
Procainamide—Vomiting—Epirubicin—thyroid cancer	0.000898	0.00174	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—thyroid cancer	0.000894	0.00173	CcSEcCtD
Procainamide—Dizziness—Doxorubicin—thyroid cancer	0.000864	0.00167	CcSEcCtD
Procainamide—Nausea—Epirubicin—thyroid cancer	0.000839	0.00162	CcSEcCtD
Procainamide—Vomiting—Doxorubicin—thyroid cancer	0.000831	0.00161	CcSEcCtD
Procainamide—Nausea—Doxorubicin—thyroid cancer	0.000776	0.0015	CcSEcCtD
Procainamide—SLC22A3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000205	0.00314	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000204	0.00312	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—PPARG—thyroid cancer	0.0002	0.00307	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000192	0.00294	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000189	0.00289	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—NRAS—thyroid cancer	0.000188	0.00288	CbGpPWpGaD
Procainamide—BCHE—Metabolism—MINPP1—thyroid cancer	0.000185	0.00283	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—SST—thyroid cancer	0.000185	0.00283	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—KRAS—thyroid cancer	0.000181	0.00278	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000179	0.00274	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NDUFA13—thyroid cancer	0.000176	0.0027	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CALCB—thyroid cancer	0.000175	0.00269	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000173	0.00266	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—CDK1—thyroid cancer	0.000172	0.00264	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—NRAS—thyroid cancer	0.000172	0.00263	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—HPGD—thyroid cancer	0.00017	0.0026	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CHST14—thyroid cancer	0.000166	0.00254	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—MINPP1—thyroid cancer	0.000165	0.00253	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—PPARG—thyroid cancer	0.000162	0.00248	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—KRAS—thyroid cancer	0.000162	0.00248	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—RXRA—thyroid cancer	0.00016	0.00245	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CALCB—thyroid cancer	0.000159	0.00244	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NDUFA13—thyroid cancer	0.000157	0.00241	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000156	0.00239	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000155	0.00238	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—PPARG—thyroid cancer	0.000155	0.00237	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—HRAS—thyroid cancer	0.000154	0.00236	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—MINPP1—thyroid cancer	0.000154	0.00236	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000154	0.00236	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000154	0.00236	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—RXRA—thyroid cancer	0.000151	0.00231	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—NRAS—thyroid cancer	0.00015	0.0023	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—PPARG—thyroid cancer	0.000149	0.00228	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—PPARG—thyroid cancer	0.000149	0.00228	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CHST14—thyroid cancer	0.000148	0.00226	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—KRAS—thyroid cancer	0.000148	0.00226	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000147	0.00225	CbGpPWpGaD
Procainamide—ACHE—Phospholipid metabolism—PTEN—thyroid cancer	0.000146	0.00223	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—TSHR—thyroid cancer	0.000144	0.0022	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—PPARG—thyroid cancer	0.000143	0.0022	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—PPARG—thyroid cancer	0.000143	0.0022	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NDUFA13—thyroid cancer	0.00014	0.00215	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—NRAS—thyroid cancer	0.000139	0.00213	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—HRAS—thyroid cancer	0.000137	0.0021	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000137	0.0021	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—NRAS—thyroid cancer	0.000134	0.00205	CbGpPWpGaD
Procainamide—ACHE—Metabolism—HPGD—thyroid cancer	0.000133	0.00205	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—NRAS—thyroid cancer	0.000133	0.00203	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—BRAF—thyroid cancer	0.000132	0.00202	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CHST14—thyroid cancer	0.000132	0.00202	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NDUFA13—thyroid cancer	0.000131	0.002	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000131	0.002	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00013	0.002	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.00013	0.002	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00013	0.002	CbGpPWpGaD
Procainamide—BCHE—Phospholipid metabolism—PTEN—thyroid cancer	0.00013	0.00199	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—KRAS—thyroid cancer	0.000129	0.00198	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000129	0.00197	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000128	0.00197	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—NRAS—thyroid cancer	0.000128	0.00196	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—NRAS—thyroid cancer	0.000128	0.00196	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—HRAS—thyroid cancer	0.000126	0.00192	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—NRAS—thyroid cancer	0.000123	0.00189	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—NRAS—thyroid cancer	0.000123	0.00189	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CHST14—thyroid cancer	0.000123	0.00188	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—NRAS—thyroid cancer	0.000122	0.00188	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000122	0.00188	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—PTCH1—thyroid cancer	0.000122	0.00187	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000122	0.00186	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000122	0.00186	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00012	0.00183	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—KRAS—thyroid cancer	0.000119	0.00183	CbGpPWpGaD
Procainamide—BCHE—Metabolism—HPGD—thyroid cancer	0.000119	0.00183	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—BRAF—thyroid cancer	0.000118	0.0018	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000116	0.00178	CbGpPWpGaD
Procainamide—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000116	0.00177	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—KRAS—thyroid cancer	0.000115	0.00177	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—KRAS—thyroid cancer	0.000114	0.00175	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—BRAF—thyroid cancer	0.000114	0.00175	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000112	0.00172	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—SST—thyroid cancer	0.000112	0.00171	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—HRAS—thyroid cancer	0.00011	0.00168	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—KRAS—thyroid cancer	0.00011	0.00168	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—KRAS—thyroid cancer	0.00011	0.00168	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000108	0.00166	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CALCA—thyroid cancer	0.000108	0.00165	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—HPGD—thyroid cancer	0.000106	0.00163	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—KRAS—thyroid cancer	0.000106	0.00162	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—KRAS—thyroid cancer	0.000106	0.00162	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—KRAS—thyroid cancer	0.000105	0.00162	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—BRAF—thyroid cancer	0.000105	0.00161	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—HRAS—thyroid cancer	0.000102	0.00156	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—PPARG—thyroid cancer	0.000101	0.00155	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—HPGD—thyroid cancer	9.91e-05	0.00152	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—NRAS—thyroid cancer	9.91e-05	0.00152	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—HRAS—thyroid cancer	9.8e-05	0.0015	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.76e-05	0.0015	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—TPR—thyroid cancer	9.74e-05	0.00149	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—HRAS—thyroid cancer	9.71e-05	0.00149	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—AKT1—thyroid cancer	9.71e-05	0.00149	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	9.66e-05	0.00148	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PRKAR1A—thyroid cancer	9.58e-05	0.00147	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—PPARG—thyroid cancer	9.52e-05	0.00146	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—NRAS—thyroid cancer	9.48e-05	0.00145	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CALCB—thyroid cancer	9.41e-05	0.00144	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—BRAF—thyroid cancer	9.38e-05	0.00144	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—HRAS—thyroid cancer	9.33e-05	0.00143	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—HRAS—thyroid cancer	9.33e-05	0.00143	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—NRAS—thyroid cancer	9.1e-05	0.0014	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—NRAS—thyroid cancer	9.1e-05	0.0014	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	9.1e-05	0.00139	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—HRAS—thyroid cancer	9e-05	0.00138	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—HRAS—thyroid cancer	9e-05	0.00138	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—HRAS—thyroid cancer	8.96e-05	0.00137	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TRIM33—thyroid cancer	8.92e-05	0.00137	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—NRAS—thyroid cancer	8.78e-05	0.00135	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—NRAS—thyroid cancer	8.78e-05	0.00135	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—BRAF—thyroid cancer	8.74e-05	0.00134	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—AKT1—thyroid cancer	8.65e-05	0.00133	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—NRAS—thyroid cancer	8.65e-05	0.00133	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	8.62e-05	0.00132	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—KRAS—thyroid cancer	8.53e-05	0.00131	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—MINPP1—thyroid cancer	8.5e-05	0.0013	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—NRAS—thyroid cancer	8.3e-05	0.00127	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	8.2e-05	0.00126	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—KRAS—thyroid cancer	8.15e-05	0.00125	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—TSHR—thyroid cancer	8.12e-05	0.00124	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—AKT1—thyroid cancer	7.91e-05	0.00121	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—KRAS—thyroid cancer	7.83e-05	0.0012	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—KRAS—thyroid cancer	7.83e-05	0.0012	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TPR—thyroid cancer	7.67e-05	0.00117	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.67e-05	0.00117	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	7.65e-05	0.00117	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—KRAS—thyroid cancer	7.55e-05	0.00116	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—KRAS—thyroid cancer	7.55e-05	0.00116	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PRKAR1A—thyroid cancer	7.54e-05	0.00116	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—KRAS—thyroid cancer	7.44e-05	0.00114	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—TSHR—thyroid cancer	7.37e-05	0.00113	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—SLC5A5—thyroid cancer	7.29e-05	0.00112	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PRKAR1A—thyroid cancer	7.25e-05	0.00111	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—HRAS—thyroid cancer	7.25e-05	0.00111	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NDUFA13—thyroid cancer	7.22e-05	0.00111	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—KRAS—thyroid cancer	7.15e-05	0.0011	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—HRAS—thyroid cancer	7.07e-05	0.00108	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—HRAS—thyroid cancer	6.93e-05	0.00106	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TPR—thyroid cancer	6.84e-05	0.00105	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.84e-05	0.00105	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CHST14—thyroid cancer	6.79e-05	0.00104	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PRKAR1A—thyroid cancer	6.73e-05	0.00103	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—HRAS—thyroid cancer	6.66e-05	0.00102	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—HRAS—thyroid cancer	6.66e-05	0.00102	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.47e-05	0.000992	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—HRAS—thyroid cancer	6.42e-05	0.000984	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—HRAS—thyroid cancer	6.42e-05	0.000984	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—AKT1—thyroid cancer	6.4e-05	0.000981	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—HRAS—thyroid cancer	6.33e-05	0.00097	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—SST—thyroid cancer	6.31e-05	0.000968	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—HRAS—thyroid cancer	6.3e-05	0.000966	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTCH1—thyroid cancer	6.27e-05	0.000961	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—NRAS—thyroid cancer	6.17e-05	0.000946	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—RXRA—thyroid cancer	6.13e-05	0.000939	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—AKT1—thyroid cancer	6.12e-05	0.000938	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TPR—thyroid cancer	6.11e-05	0.000936	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.1e-05	0.000935	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CALCA—thyroid cancer	6.08e-05	0.000931	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PRKAR1A—thyroid cancer	6.01e-05	0.000921	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TCF7L1—thyroid cancer	5.95e-05	0.000912	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—AKT1—thyroid cancer	5.88e-05	0.000901	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—AKT1—thyroid cancer	5.88e-05	0.000901	CbGpPWpGaD
Procainamide—ACHE—Metabolism—SLC5A5—thyroid cancer	5.74e-05	0.00088	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—SST—thyroid cancer	5.73e-05	0.000879	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TPR—thyroid cancer	5.69e-05	0.000873	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—AKT1—thyroid cancer	5.67e-05	0.000869	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—AKT1—thyroid cancer	5.67e-05	0.000869	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.63e-05	0.000863	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PRKAR1A—thyroid cancer	5.6e-05	0.000858	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CALCA—thyroid cancer	5.52e-05	0.000846	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HPGD—thyroid cancer	5.48e-05	0.000839	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—HRAS—thyroid cancer	5.41e-05	0.00083	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.38e-05	0.000824	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—KRAS—thyroid cancer	5.31e-05	0.000814	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—HRAS—thyroid cancer	5.25e-05	0.000804	CbGpPWpGaD
Procainamide—BCHE—Metabolism—SLC5A5—thyroid cancer	5.12e-05	0.000785	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CDK1—thyroid cancer	5e-05	0.000766	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—HRAS—thyroid cancer	4.83e-05	0.00074	CbGpPWpGaD
Procainamide—ACHE—Metabolism—RXRA—thyroid cancer	4.82e-05	0.000739	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.8e-05	0.000735	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.69e-05	0.000719	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—SLC5A5—thyroid cancer	4.57e-05	0.000701	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—HRAS—thyroid cancer	4.51e-05	0.000692	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TSHR—thyroid cancer	4.36e-05	0.000667	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—HRAS—thyroid cancer	4.31e-05	0.000661	CbGpPWpGaD
Procainamide—BCHE—Metabolism—RXRA—thyroid cancer	4.3e-05	0.000659	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PRKAR1A—thyroid cancer	4.28e-05	0.000657	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SLC5A5—thyroid cancer	4.26e-05	0.000653	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.18e-05	0.000641	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MEN1—thyroid cancer	4.09e-05	0.000628	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—HRAS—thyroid cancer	4.02e-05	0.000616	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—AKT1—thyroid cancer	3.99e-05	0.000611	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PPARG—thyroid cancer	3.87e-05	0.000593	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—RXRA—thyroid cancer	3.84e-05	0.000589	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—AKT1—thyroid cancer	3.76e-05	0.000577	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTCH1—thyroid cancer	3.7e-05	0.000568	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—RXRA—thyroid cancer	3.58e-05	0.000549	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SST—thyroid cancer	3.39e-05	0.000519	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CALCA—thyroid cancer	3.26e-05	0.0005	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TPR—thyroid cancer	3.14e-05	0.000482	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	3.09e-05	0.000474	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PPARG—thyroid cancer	3.04e-05	0.000467	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTGS2—thyroid cancer	3.04e-05	0.000466	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDK1—thyroid cancer	2.95e-05	0.000452	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PPARG—thyroid cancer	2.72e-05	0.000416	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTEN—thyroid cancer	2.65e-05	0.000407	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PPARG—thyroid cancer	2.43e-05	0.000372	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTGS2—thyroid cancer	2.4e-05	0.000367	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRG1—thyroid cancer	2.37e-05	0.000363	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.35e-05	0.000361	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PPARG—thyroid cancer	2.26e-05	0.000347	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTGS2—thyroid cancer	2.14e-05	0.000327	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TERT—thyroid cancer	2.13e-05	0.000326	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTEN—thyroid cancer	2.09e-05	0.00032	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HIF1A—thyroid cancer	2.03e-05	0.000312	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—RXRA—thyroid cancer	1.98e-05	0.000303	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTGS2—thyroid cancer	1.91e-05	0.000292	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTEN—thyroid cancer	1.86e-05	0.000286	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—NRAS—thyroid cancer	1.79e-05	0.000275	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTGS2—thyroid cancer	1.78e-05	0.000273	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—BRAF—thyroid cancer	1.68e-05	0.000258	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTEN—thyroid cancer	1.66e-05	0.000255	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTEN—thyroid cancer	1.55e-05	0.000238	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KRAS—thyroid cancer	1.54e-05	0.000236	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—AKT1—thyroid cancer	1.53e-05	0.000234	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—thyroid cancer	1.31e-05	0.000201	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AKT1—thyroid cancer	1.27e-05	0.000195	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PPARG—thyroid cancer	1.25e-05	0.000191	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCND1—thyroid cancer	1.23e-05	0.000188	CbGpPWpGaD
Procainamide—ACHE—Metabolism—AKT1—thyroid cancer	1.2e-05	0.000184	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTEN—thyroid cancer	1.19e-05	0.000182	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AKT1—thyroid cancer	1.16e-05	0.000177	CbGpPWpGaD
Procainamide—BCHE—Metabolism—AKT1—thyroid cancer	1.07e-05	0.000165	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRAS—thyroid cancer	1.06e-05	0.000162	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTGS2—thyroid cancer	9.82e-06	0.000151	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—AKT1—thyroid cancer	9.59e-06	0.000147	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KRAS—thyroid cancer	9.11e-06	0.00014	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—AKT1—thyroid cancer	8.94e-06	0.000137	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTEN—thyroid cancer	8.57e-06	0.000131	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—thyroid cancer	8.1e-06	0.000124	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—thyroid cancer	7.74e-06	0.000119	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AKT1—thyroid cancer	6.84e-06	0.000105	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—AKT1—thyroid cancer	4.94e-06	7.57e-05	CbGpPWpGaD
